JP2006077019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006077019A5 JP2006077019A5 JP2005272533A JP2005272533A JP2006077019A5 JP 2006077019 A5 JP2006077019 A5 JP 2006077019A5 JP 2005272533 A JP2005272533 A JP 2005272533A JP 2005272533 A JP2005272533 A JP 2005272533A JP 2006077019 A5 JP2006077019 A5 JP 2006077019A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- substituted
- alkyl
- halogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 182
- 125000000623 heterocyclic group Chemical group 0.000 claims 173
- 125000005843 halogen group Chemical group 0.000 claims 117
- 125000001424 substituent group Chemical group 0.000 claims 116
- 125000003118 aryl group Chemical class 0.000 claims 95
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 71
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 70
- -1 —CF 3 Chemical group 0.000 claims 62
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 50
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 49
- 125000004093 cyano group Chemical group *C#N 0.000 claims 40
- 125000003545 alkoxy group Chemical group 0.000 claims 38
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000003282 alkyl amino group Chemical group 0.000 claims 32
- 125000004043 oxo group Chemical group O=* 0.000 claims 31
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 29
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 27
- 229910052799 carbon Inorganic materials 0.000 claims 17
- 125000003342 alkenyl group Chemical class 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical class 0.000 claims 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 208000037357 HIV infectious disease Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LFMFIMQKPGUOAL-UHFFFAOYSA-N 2-(2-benzoyl-4-chlorophenoxy)-n-[4-(1-hydroxyethyl)phenyl]acetamide Chemical compound C1=CC(C(O)C)=CC=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 LFMFIMQKPGUOAL-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- IQVFNCHDINMLAG-UHFFFAOYSA-N 2-(2-benzoyl-4-chlorophenoxy)-n-(1h-indazol-5-yl)acetamide Chemical compound C=1C(Cl)=CC=C(OCC(=O)NC=2C=C3C=NNC3=CC=2)C=1C(=O)C1=CC=CC=C1 IQVFNCHDINMLAG-UHFFFAOYSA-N 0.000 claims 1
- KSVBEMHNPBHJOI-UHFFFAOYSA-N 2-(2-benzoyl-4-chlorophenoxy)-n-(1h-indazol-6-yl)acetamide Chemical compound C=1C(Cl)=CC=C(OCC(=O)NC=2C=C3NN=CC3=CC=2)C=1C(=O)C1=CC=CC=C1 KSVBEMHNPBHJOI-UHFFFAOYSA-N 0.000 claims 1
- QXEKIOQBLYMXIB-UHFFFAOYSA-N 2-(2-benzoyl-4-chlorophenoxy)-n-[4-(hydroxymethyl)phenyl]acetamide Chemical compound C1=CC(CO)=CC=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 QXEKIOQBLYMXIB-UHFFFAOYSA-N 0.000 claims 1
- RZMFFVBBWIDKNJ-UHFFFAOYSA-N 2-(2-benzoyl-4-chlorophenoxy)-n-[4-[3-(dimethylamino)propoxy]-2-methylphenyl]acetamide Chemical compound CC1=CC(OCCCN(C)C)=CC=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 RZMFFVBBWIDKNJ-UHFFFAOYSA-N 0.000 claims 1
- IUIXYTQGJCFJMN-UHFFFAOYSA-N 2-[2-(1-benzofuran-2-carbonyl)-4-chlorophenoxy]-n-phenylacetamide Chemical compound C=1C2=CC=CC=C2OC=1C(=O)C1=CC(Cl)=CC=C1OCC(=O)NC1=CC=CC=C1 IUIXYTQGJCFJMN-UHFFFAOYSA-N 0.000 claims 1
- GGPHXQUFZNHWMY-UHFFFAOYSA-N 2-[2-(1-benzothiophene-2-carbonyl)-4-chlorophenoxy]-n-phenylacetamide Chemical compound C=1C2=CC=CC=C2SC=1C(=O)C1=CC(Cl)=CC=C1OCC(=O)NC1=CC=CC=C1 GGPHXQUFZNHWMY-UHFFFAOYSA-N 0.000 claims 1
- XMLCGOXNAORDEL-UHFFFAOYSA-N 2-[4-chloro-2-(1,3-thiazole-2-carbonyl)phenoxy]-n-phenylacetamide Chemical compound N=1C=CSC=1C(=O)C1=CC(Cl)=CC=C1OCC(=O)NC1=CC=CC=C1 XMLCGOXNAORDEL-UHFFFAOYSA-N 0.000 claims 1
- FQZKJONCWUXTQN-UHFFFAOYSA-N 2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]-n-(5-methyl-1h-indazol-6-yl)acetamide Chemical compound CC1=CC=2C=NNC=2C=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC(Cl)=CC(Cl)=C1 FQZKJONCWUXTQN-UHFFFAOYSA-N 0.000 claims 1
- WBDKKXLJMKGHQW-UHFFFAOYSA-N 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-1-(2,3-dihydroindol-1-yl)ethanone Chemical compound FC1=CC(F)=CC(C(=O)C=2C(=CC=C(Cl)C=2)OCC(=O)N2C3=CC=CC=C3CC2)=C1 WBDKKXLJMKGHQW-UHFFFAOYSA-N 0.000 claims 1
- WDVFJSOMJOLYNI-UHFFFAOYSA-N 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-n-(5-methyl-1h-indazol-6-yl)acetamide Chemical compound CC1=CC=2C=NNC=2C=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC(F)=CC(F)=C1 WDVFJSOMJOLYNI-UHFFFAOYSA-N 0.000 claims 1
- SMLSXYQFAVPGLY-UHFFFAOYSA-N 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-n-[4-(1,3-oxazol-2-yl)phenyl]acetamide Chemical compound FC1=CC(F)=CC(C(=O)C=2C(=CC=C(Cl)C=2)OCC(=O)NC=2C=CC(=CC=2)C=2OC=CN=2)=C1 SMLSXYQFAVPGLY-UHFFFAOYSA-N 0.000 claims 1
- GAJKHSVAJBMBMM-UHFFFAOYSA-N 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-n-[4-(1,3-thiazol-2-yl)phenyl]acetamide Chemical compound FC1=CC(F)=CC(C(=O)C=2C(=CC=C(Cl)C=2)OCC(=O)NC=2C=CC(=CC=2)C=2SC=CN=2)=C1 GAJKHSVAJBMBMM-UHFFFAOYSA-N 0.000 claims 1
- NISMLHBLUCFLGW-UHFFFAOYSA-N 2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-n-(2-methyl-1,3-benzothiazol-5-yl)acetamide Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC=CC(C#N)=C1 NISMLHBLUCFLGW-UHFFFAOYSA-N 0.000 claims 1
- OQOUVXPUPLDUGS-UHFFFAOYSA-N 2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-n-(5-methyl-1h-indazol-6-yl)acetamide Chemical compound CC1=CC=2C=NNC=2C=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC=CC(C#N)=C1 OQOUVXPUPLDUGS-UHFFFAOYSA-N 0.000 claims 1
- IGYLHFKQHSPTCS-UHFFFAOYSA-N 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-n-(5-methyl-1h-indazol-6-yl)acetamide Chemical compound CC1=CC=2C=NNC=2C=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC(F)=CC(C(F)(F)F)=C1 IGYLHFKQHSPTCS-UHFFFAOYSA-N 0.000 claims 1
- GZSOQJPKIGDUCR-UHFFFAOYSA-N 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-n-(6-methyl-1,3-benzothiazol-5-yl)acetamide Chemical compound CC1=CC=2SC=NC=2C=C1NC(=O)COC1=CC=C(Cl)C=C1C(=O)C1=CC(F)=CC(C(F)(F)F)=C1 GZSOQJPKIGDUCR-UHFFFAOYSA-N 0.000 claims 1
- 125000002981 3-(trifluoromethyl)benzoyl group Chemical group FC(C=1C=C(C(=O)*)C=CC1)(F)F 0.000 claims 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- YIVXTPCRSIHQRZ-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-2-(2-benzoyl-4-chlorophenoxy)acetamide Chemical compound C=1C(Cl)=CC=C(OCC(=O)NC=2C=C3SC=NC3=CC=2)C=1C(=O)C1=CC=CC=C1 YIVXTPCRSIHQRZ-UHFFFAOYSA-N 0.000 claims 1
- GVOPOUQQTHXFNU-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]acetamide Chemical compound FC1=CC(F)=CC(C(=O)C=2C(=CC=C(Cl)C=2)OCC(=O)NC=2C=C3SC=NC3=CC=2)=C1 GVOPOUQQTHXFNU-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 CC(c1ccccc1*C(*)C(N(*)*)=O)=O Chemical compound CC(c1ccccc1*C(*)C(N(*)*)=O)=O 0.000 description 2
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9920872.0A GB9920872D0 (en) | 1999-09-04 | 1999-09-04 | Benzophenones as inhibitors of reverse transcriptase |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001521729A Division JP3739704B2 (ja) | 1999-09-04 | 2000-08-31 | 逆転写酵素のインヒビターとしてのベンゾフェノン類 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006077019A JP2006077019A (ja) | 2006-03-23 |
| JP2006077019A5 true JP2006077019A5 (enExample) | 2007-11-08 |
Family
ID=10860319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001521729A Expired - Fee Related JP3739704B2 (ja) | 1999-09-04 | 2000-08-31 | 逆転写酵素のインヒビターとしてのベンゾフェノン類 |
| JP2005272533A Withdrawn JP2006077019A (ja) | 1999-09-04 | 2005-09-20 | 逆転写酵素のインヒビターとしてのベンゾフェノン類 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001521729A Expired - Fee Related JP3739704B2 (ja) | 1999-09-04 | 2000-08-31 | 逆転写酵素のインヒビターとしてのベンゾフェノン類 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7273863B1 (enExample) |
| EP (2) | EP1208091B1 (enExample) |
| JP (2) | JP3739704B2 (enExample) |
| KR (2) | KR20020086850A (enExample) |
| CN (4) | CN1636985A (enExample) |
| AR (1) | AR033344A1 (enExample) |
| AT (1) | ATE325106T1 (enExample) |
| AU (1) | AU770302C (enExample) |
| BR (1) | BR0013771A (enExample) |
| CA (1) | CA2383782A1 (enExample) |
| CZ (1) | CZ2002807A3 (enExample) |
| DE (1) | DE60027729T2 (enExample) |
| ES (1) | ES2261242T3 (enExample) |
| GB (1) | GB9920872D0 (enExample) |
| HU (1) | HUP0202593A3 (enExample) |
| IL (1) | IL148322A0 (enExample) |
| MX (1) | MXPA02002347A (enExample) |
| MY (1) | MY142948A (enExample) |
| NO (1) | NO323156B1 (enExample) |
| NZ (1) | NZ517451A (enExample) |
| PE (1) | PE20010539A1 (enExample) |
| PL (1) | PL354760A1 (enExample) |
| TR (1) | TR200201187T2 (enExample) |
| TW (1) | TWI286550B (enExample) |
| WO (1) | WO2001017982A1 (enExample) |
| ZA (1) | ZA200201664B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6589801A (en) * | 2000-04-28 | 2001-11-12 | F. Hoffmann-La Roche Ag | P-(sulfonyl)aryl and heteroaryls |
| TW200408645A (en) | 2002-04-26 | 2004-06-01 | Gilead Sciences Inc | Non nucleoside reverse transcriptase inhibitors |
| EP1628953A4 (en) * | 2003-03-27 | 2006-11-02 | Smithkline Beecham Corp | PROCESS FOR PREPARING REVERSE TRANSCRIPTASE INHIBITORS |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| EP1620109A2 (en) | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| WO2005042773A1 (en) | 2003-10-24 | 2005-05-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
| CN101061101B (zh) | 2003-12-22 | 2011-09-07 | 巴斯利尔药物股份公司 | 芳酰基呋喃和芳酰基噻吩 |
| BRPI0417988A (pt) | 2003-12-22 | 2007-04-27 | Gilead Sciences Inc | análogos de fosfonato antivirais |
| FR2866880A1 (fr) * | 2004-02-27 | 2005-09-02 | Oreal | Para-phenylenediamine secondaire n-alkylaminee ortho-et/ou meta-substituee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations |
| AU2005235692B2 (en) * | 2004-04-23 | 2011-11-10 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
| US7625949B2 (en) | 2004-04-23 | 2009-12-01 | Roche Palo Alto Llc | Methods for treating retroviral infections |
| WO2005121094A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Limited | Piperazine and piperidine derivatives as anti-hiv-agents |
| PT2258376T (pt) | 2004-07-27 | 2019-05-31 | Gilead Sciences Inc | Análogos fosfonatados de compostos inibidores do vih |
| US20060025480A1 (en) | 2004-08-02 | 2006-02-02 | Boehringer Ingelheim International Gmbh | Benzoic acid derivatives as non nucleoside reverse transcriptase inhibitors |
| WO2006034583A1 (en) * | 2004-09-30 | 2006-04-06 | Boehringer Ingelheim International Gmbh & Co Kg | Alkynyl based dervatives of benzophenone as non-nucleoside reverse transcriptase inhibitors |
| JP2008521896A (ja) * | 2004-12-01 | 2008-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | チプラナビル及びｇｗ６９５６３４を共に投与することを含むｈｉｖ感染症の治療方法 |
| AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| EP1940781A1 (en) | 2005-10-19 | 2008-07-09 | F.Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
| CN101108178B (zh) * | 2006-07-20 | 2010-09-15 | 复旦大学 | 一种亲环素a抑制剂在制备抗艾滋病药物中的应用 |
| WO2009084695A1 (ja) | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | ２－アミノキナゾリン誘導体 |
| BRPI0915878A2 (pt) | 2008-07-08 | 2015-11-03 | Gilead Sciences Inc | sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende |
| WO2011060394A1 (en) * | 2009-11-16 | 2011-05-19 | Schering Corporation | Compounds useful as chemokine receptor antagonists |
| CN102229547A (zh) * | 2011-04-20 | 2011-11-02 | 复旦大学 | 一种萘苯醚类苯磺酰胺衍生物及其制备方法和用途 |
| CN102212022A (zh) * | 2011-04-20 | 2011-10-12 | 复旦大学 | 二苯甲醇衍生物及其制备方法和用途 |
| CN102219717A (zh) * | 2011-04-20 | 2011-10-19 | 复旦大学 | N-苯基芳基甲酰胺衍生物及其制备方法和用途 |
| CN102206177A (zh) * | 2011-04-20 | 2011-10-05 | 复旦大学 | 1-萘基苯甲酮衍生物及其制备方法和用途 |
| WO2015138220A1 (en) * | 2014-03-10 | 2015-09-17 | Merck Sharp & Dohme Corp. | Piperazine derivatives as hiv protease inhibitors |
| PT3661937T (pt) | 2017-08-01 | 2021-09-24 | Gilead Sciences Inc | Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais |
| US12310967B2 (en) | 2017-12-21 | 2025-05-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| US12274703B2 (en) | 2017-12-21 | 2025-04-15 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| RU2729792C1 (ru) * | 2019-07-29 | 2020-08-12 | Акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" | Способы повышения растворимости лекарственного средства на основе пиримидинового производного бензофенона |
| CN113444010B (zh) * | 2020-03-28 | 2023-09-05 | 南京正大天晴制药有限公司 | 一种沙芬酰胺有关物质的制备方法 |
| CN113461502B (zh) * | 2021-07-15 | 2023-07-28 | 台州臻挚生物科技有限公司 | 2-羟基二苯甲酮类化合物及其卤化衍生物的制备方法 |
| CN114163361B (zh) * | 2021-12-14 | 2023-08-01 | 无锡捷化医药科技有限公司 | 一种3-溴-5-羟基苯磺酰胺的制备方法 |
| CN114292248A (zh) * | 2022-01-18 | 2022-04-08 | 广东莱佛士制药技术有限公司 | 一种合成莱特莫韦中间体的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1552793A (enExample) * | 1966-12-07 | 1969-01-10 | ||
| US4207234A (en) * | 1975-07-07 | 1980-06-10 | Fujisawa Pharmaceutical Co., Ltd. | 4-Unsubstituted azetidinone derivatives and process for preparation thereof |
| JPS5973579A (ja) * | 1982-10-19 | 1984-04-25 | Kotobuki Seiyaku Kk | ベンゾフラン又はベンゾチオフェン誘導体，この化合物を有効成分とする尿酸排泄剤及びその製造方法 |
| JPS59181246A (ja) | 1983-03-31 | 1984-10-15 | Chugai Pharmaceut Co Ltd | ベンゾフエノン誘導体 |
| IN167395B (enExample) * | 1987-07-21 | 1990-10-20 | Hoffmann La Roche | |
| WO1993015043A1 (fr) | 1992-01-24 | 1993-08-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose arylalkananilide et utilisation pharmaceutique |
| FR2716195B1 (fr) | 1994-02-14 | 1996-06-21 | Sanofi Sa | Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| CN1048239C (zh) | 1994-05-31 | 2000-01-12 | 帝人株式会社 | 萘衍生物 |
| CA2330458A1 (en) * | 1998-04-29 | 1999-11-04 | Georgetown University | Methods of identifying and using hla binding compounds as hla-agonists and antagonists |
-
1999
- 1999-09-04 GB GBGB9920872.0A patent/GB9920872D0/en not_active Ceased
-
2000
- 2000-08-31 EP EP00967637A patent/EP1208091B1/en not_active Expired - Lifetime
- 2000-08-31 EP EP06075956A patent/EP1710238A1/en not_active Withdrawn
- 2000-08-31 CN CNA2004100956223A patent/CN1636985A/zh active Pending
- 2000-08-31 JP JP2001521729A patent/JP3739704B2/ja not_active Expired - Fee Related
- 2000-08-31 WO PCT/EP2000/008487 patent/WO2001017982A1/en not_active Ceased
- 2000-08-31 CN CNA2004100974700A patent/CN1636986A/zh active Pending
- 2000-08-31 ES ES00967637T patent/ES2261242T3/es not_active Expired - Lifetime
- 2000-08-31 PL PL00354760A patent/PL354760A1/xx not_active Application Discontinuation
- 2000-08-31 CN CNA2004100956219A patent/CN1636984A/zh active Pending
- 2000-08-31 IL IL14832200A patent/IL148322A0/xx unknown
- 2000-08-31 KR KR1020027002871A patent/KR20020086850A/ko not_active Abandoned
- 2000-08-31 CA CA002383782A patent/CA2383782A1/en not_active Abandoned
- 2000-08-31 US US10/070,084 patent/US7273863B1/en not_active Expired - Fee Related
- 2000-08-31 MX MXPA02002347A patent/MXPA02002347A/es active IP Right Grant
- 2000-08-31 AT AT00967637T patent/ATE325106T1/de not_active IP Right Cessation
- 2000-08-31 HU HU0202593A patent/HUP0202593A3/hu unknown
- 2000-08-31 CN CNB008152497A patent/CN1213038C/zh not_active Expired - Fee Related
- 2000-08-31 BR BR0013771-5A patent/BR0013771A/pt not_active Application Discontinuation
- 2000-08-31 NZ NZ517451A patent/NZ517451A/en unknown
- 2000-08-31 CZ CZ2002807A patent/CZ2002807A3/cs unknown
- 2000-08-31 KR KR1020077019984A patent/KR20070093152A/ko not_active Ceased
- 2000-08-31 AU AU77743/00A patent/AU770302C/en not_active Ceased
- 2000-08-31 DE DE60027729T patent/DE60027729T2/de not_active Expired - Fee Related
- 2000-08-31 TR TR2002/01187T patent/TR200201187T2/xx unknown
- 2000-09-01 TW TW089117846A patent/TWI286550B/zh not_active IP Right Cessation
- 2000-09-01 MY MYPI20004058A patent/MY142948A/en unknown
- 2000-09-01 AR ARP000104592A patent/AR033344A1/es not_active Application Discontinuation
- 2000-09-01 PE PE2000000897A patent/PE20010539A1/es not_active Application Discontinuation
-
2002
- 2002-02-27 ZA ZA200201664A patent/ZA200201664B/en unknown
- 2002-03-01 NO NO20021042A patent/NO323156B1/no unknown
-
2005
- 2005-09-20 JP JP2005272533A patent/JP2006077019A/ja not_active Withdrawn